CAR-T clinical trials

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

CAR-T cell therapy for B-cell lymphoma that returned or didn't respond

This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.

CAR T-cell therapy for children with relapsed or refractory ALL

This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.

CAR-T treatment study for children and young adults with CD19 leukemia

This Phase 1 study tests a CAR-T cell treatment made to target CD19 in children and young adults whose leukemia or lymphoma has come back or did not respond to prior treatment. It aims to see how the treatment works and how safe it is in this age group.

Modified immune cells for T-cell lymphoma

This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.

CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma

This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.

Sequential CD19 CAR-NK and CAR-T for B-cell lymphoma

This trial tests a new combination treatment: first, natural killer cells (NK cells) that are engineered to find CD19, followed by CAR-T cells (also targeting CD19). It is for people with B-cell lymphoma that has come back or not responded to standard treatments.

CAR-T cell therapy for immune kidney disease

This trial tests a special cell treatment (CAR-T) for people with immune-related kidney disease that has not responded to standard therapy. The treatment aims to remove faulty immune cells that damage the kidneys.

Donor CAR-T cells for B-cell leukemia

This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.

CAR-T therapy with or without stem cell transplant for B-cell leukemia

This trial tests a CD19-targeted CAR-T cell therapy (S1904) for people with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. After CAR-T, some patients may go on to a stem cell transplant. The goal is to see if the CAR-T can lead to remission and who needs a transplant.

CAR T cells targeting CD146 and HER2 for advanced sarcomas

This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.

CD7 CAR-T therapy for T-cell cancers that returned

This trial tests a new kind of immunotherapy called CD7 CAR-T therapy for people with T-cell cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The CAR-T cells are made from your own immune cells or a donor's, and they are designed to find and destroy cancer cells that carry the CD7 marker.

CAR-T cell therapy for relapsed B-cell blood cancers

This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.

CAR-T therapy for autoimmune disease after prior treatment

This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.

CAR-T cell therapy for autoimmune diseases

This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.

PSCA CAR-T cells with or without radiation for prostate cancer

This Phase 1 study tests a prostate cancer treatment made of PSCA-targeted CAR-T cells, with or without radiation, to help control advanced prostate cancer. It aims to find a safe treatment approach and see how well it works in people whose cancer has PSCA.

CAR T cells for lupus

This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.

Fecal transplant for lymphoma patients getting CAR T therapy

This trial tests whether giving a fecal transplant (a stool enema from a healthy donor) can improve the response to CAR T-cell therapy in people with B-cell lymphoma. It may help by restoring healthy gut bacteria that are often wiped out by strong antibiotics.

CAR-T cell therapy for T-cell leukemia and lymphoma

This trial tests a new CAR-T cell therapy (WU-CART-007) made from donor cells that target a protein called CD7 on cancer cells. It is for children and adults with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or is still present after treatment.

Studying blood cell changes after CAR-T therapy for blood cancers

This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.

Dasatinib and quercetin with Carvykti for advanced multiple myeloma

This trial tests whether adding two drugs (dasatinib and quercetin) before CAR-T therapy (Carvykti) can improve outcomes for people with multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this combination is safe and effective.

GD2/PSMA CAR-T therapy for hard-to-remove metastatic cancers

This early-phase study tests a custom immune-cell treatment (CAR-T) that targets two tumor markers called GD2 and PSMA. It may help people whose cancer is advanced, cannot be removed with surgery, and has the right marker pattern in their tumor tissue.

Comparing a new CAR-T therapy to standard treatments for multiple myeloma

This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.

Bridge therapy with loncastuximab and rituximab before CAR-T for lymphoma

This trial tests a two-drug combination (loncastuximab tesirine and rituximab) as a short-term "bridge" treatment for people with large B-cell lymphoma who are waiting to receive standard CAR-T cell therapy. The goal is to control the lymphoma before the CAR-T cells can be given.